Dwayne 'The Rock' Johnson TRT: What It Would Cost a Non-Celebrity

What Dwayne Johnson Has Actually Said About Testosterone and Steroids

Johnson's public statements on this topic span more than a decade and deserve careful, verbatim treatment rather than paraphrase.

In a 2009 interview published by Fortune and widely republished, Johnson confirmed he experimented with anabolic steroids at around age 23 while playing football at the University of Miami. He was direct: he tried them, did not like how they made him feel, and stopped. That admission referred specifically to anabolic-androgenic steroids (AAS) used for performance, not to medically supervised testosterone replacement.

Speculation about ongoing TRT or human growth hormone (HGH) use has circulated on bodybuilding forums and social media for years, driven largely by his physique at age 52 being dramatically more muscular than most natural athletes at the same age. Johnson has not confirmed therapeutic testosterone use in any verified public statement as of the date of this article.

Why the Distinction Between AAS and TRT Matters Clinically

Anabolic-androgenic steroids and medical TRT both raise circulating testosterone, but the clinical intent, dosing philosophy, and legal framework differ substantially.

AAS cycles used in competitive bodybuilding typically target supraphysiologic serum testosterone concentrations, sometimes exceeding 1,500 to 3,000 ng/dL. TRT prescribed under Endocrine Society guidelines targets restoration to the mid-normal range, generally 400 to 700 ng/dL, not above it. Endocrine Society Clinical Practice Guideline on Testosterone Therapy, 2018.

HGH is a separate prescription compound regulated under the Food, Drug, and Cosmetic Act. Its only FDA-approved adult indications are adult growth hormone deficiency (AGHD) and specific wasting conditions. Using it for anti-aging or body composition in the absence of a diagnosed deficiency is off-label and illegal under federal law. FDA guidance on HGH.

What a Physician Would Actually Look For

A board-certified endocrinologist or urologist evaluating a man for TRT does not start with physique or celebrity comparison. They start with symptoms.

The Endocrine Society defines male hypogonadism as a clinical syndrome that requires both low serum testosterone (confirmed on two separate morning draws) and symptoms including reduced libido, erectile dysfunction, fatigue, depressed mood, reduced lean body mass, or decreased bone density. Bhasin S et al., J Clin Endocrinol Metab, 2010.

A single low lab value without symptoms does not meet criteria for treatment.

The Real Cost of TRT for a Non-Celebrity: Formulation by Formulation

Cost is the question most men ask first. The answer depends heavily on formulation, the prescribing channel (primary care, specialist, or telehealth), and whether commercial insurance covers the medication.

Testosterone Cypionate or Enanthate Injections

Testosterone cypionate 200 mg/mL is the most cost-efficient formulation in widespread clinical use in the United States. A 10 mL multidose vial at generic pricing runs approximately $30 to $80 at most retail pharmacies with a GoodRx-type coupon, and a typical weekly or biweekly dosing schedule means one vial lasts 10 to 20 weeks.

The limiting cost is not usually the drug itself. Physician visits, lab draws (every 3 to 6 months per guidelines), and the syringe supplies add $150 to $400 per year in most primary care settings. All-in, self-injecting patients often spend $600 to $1,200 annually.

Transdermal Gels and Patches

Brand-name topical formulations such as AndroGel 1.62% or Testim carry list prices of $400 to $600 per month before insurance. Generic testosterone gel 1% is available at $80 to $200 per month at many pharmacies. These are preferred for men who cannot or will not self-inject, but the monthly cost is meaningfully higher than injection therapy.

Testosterone patches (Androderm) sit in a similar price range, roughly $200 to $400 per month for generics, with significant skin-irritation rates limiting long-term adherence in some patients.

Pellet Therapy

Subcutaneous testosterone pellets (Testopel) are inserted every 3 to 6 months under local anesthesia. Each insertion procedure costs $300 to $600 out of pocket at most men's health clinics, and pellets themselves add another $200 to $400. Annual cost is roughly $1,000 to $2,000 depending on dosing frequency. Insurance coverage is inconsistent.

Telehealth TRT Platforms

Several telehealth platforms have compressed the cost by bundling the physician visit, lab order, and medication into a monthly subscription. Prices typically run $99 to $250 per month inclusive of testosterone cypionate, shipping, and quarterly labs. This model is the most accessible for men without employer-sponsored insurance covering hormone therapy.

HealthRX's own clinical pricing for testosterone cypionate-based TRT starts at $129 per month, which includes baseline labs, follow-up consultations, and medication.

Who Actually Qualifies for TRT: The Clinical Criteria

Not every man with fatigue or reduced muscle mass qualifies for testosterone replacement. The Endocrine Society guideline is specific, and responsible prescribers follow it.

The Two-Lab Rule

Diagnosis requires two separate total testosterone measurements obtained in the morning (7 a.m. To 10 a.m., when levels peak), at least on different days, both returning below 300 ng/dL. A single borderline value does not trigger treatment.

Free testosterone is measured when total testosterone is borderline (300 to 400 ng/dL) or when sex hormone-binding globulin (SHBG) is suspected to be elevated, which can suppress bioavailable hormone even when total testosterone looks normal. Bhasin S et al., JCEM 2018.

Symptom Criteria

The most common validated screening tool is the Androgen Deficiency in Aging Males (ADAM) questionnaire, though it has moderate specificity. Symptoms the Endocrine Society lists as consistent with hypogonadism include decreased libido, poor morning erections, fatigue, loss of body hair, reduced shaving frequency, and gynecomastia. Three or more symptoms combined with two low testosterone readings supports initiation of therapy.

Absolute Contraindications

Men with prostate cancer, male breast cancer, hematocrit above 54%, severe untreated sleep apnea, or active desire for fertility should not start TRT without specialist oversight. Testosterone suppresses the hypothalamic-pituitary-gonadal (HPG) axis, which reduces sperm production. A man hoping to conceive within 12 months should discuss alternatives such as clomiphene citrate or human chorionic gonadotropin (hCG) stimulation before starting exogenous testosterone.

What the Clinical Evidence Says About TRT Benefits

The strongest trial evidence for TRT in older men comes from the Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled studies funded by the NIH and published primarily in the New England Journal of Medicine and JAMA.

In the Sexual Function Trial component (N=790), men aged 65 and older with low testosterone (<275 ng/dL) who received testosterone gel for one year showed statistically significant improvement in sexual desire, erectile function, and activity compared with placebo (P<0.001). Snyder PJ et al., NEJM 2016.

The Physical Function Trial showed improvement in walking speed (6-minute walk distance increased by a mean of 24.1 meters vs. 8.5 meters for placebo), though the clinical significance of that difference was described by the investigators as modest. Cunningham GR et al., JCEM 2016.

Bone density in the Bone Trial improved significantly at the lumbar spine and femoral neck in men receiving testosterone, a finding with relevance for men at elevated fracture risk. Snyder PJ et al., JCEM 2017.

What TRT Does Not Do

Testosterone replacement does not replicate anabolic steroid cycles. It does not produce the 30 to 40 lb lean mass gains sometimes attributed to supraphysiologic AAS protocols. Restoring testosterone to normal range in a hypogonadal man improves body composition modestly, on average 1.5 to 2 kg of lean mass gained and a similar reduction in fat mass in 12-month trials. Bhasin S et al., NEJM 1996.

Men seeking physiques comparable to elite athletes or actors like Johnson, whether through TRT or other means, should understand that genetics, decades of progressive resistance training, precise nutrition, and (in the case of competitive bodybuilders) supraphysiologic drug use all contribute. TRT alone does not account for that body composition.

Monitoring: What Happens After You Start TRT

Starting testosterone is not a one-time event. The Endocrine Society recommends monitoring at 3 to 6 months after initiation and then annually thereafter if levels are stable. Endocrine Society TRT Guideline, 2018.

Labs at Each Follow-Up Visit

A responsible TRT panel includes:

• Total and free testosterone (target: mid-normal range, typically 400 to 700 ng/dL)
• Hematocrit (hold or reduce dose if above 54%)
• PSA (prostate-specific antigen, baseline and annual after age 40)
• LH and FSH (to confirm HPG suppression and exclude secondary causes)
• Lipid panel and metabolic panel annually
• Bone mineral density (DXA) at baseline and every 1 to 2 years if osteopenia is present

Polycythemia (elevated red blood cell mass) is the most common adverse effect requiring dose adjustment. In pooled data from randomized trials, hematocrit exceeds 54% in roughly 4 to 5% of men on injectable testosterone, compared with <1% on placebo.

Long-Term Cardiovascular Signal

The TRAVERSE trial (N=5,246, published 2023) was the first adequately powered randomized trial to assess cardiovascular safety of TRT in men with hypogonadism and elevated cardiovascular risk. Major adverse cardiovascular events (MACE) occurred in 7.0% of the testosterone group vs. 7.3% of placebo, meeting the non-inferiority margin. Lincoff AM et al., NEJM 2023. This trial substantially reframed prior safety concerns that had arisen from smaller, poorly powered studies.

A signal for higher rates of atrial fibrillation (3.5% vs. 2.4%) and pulmonary embolism (0.9% vs. 0.5%) was observed, suggesting the cardiovascular story is not fully closed. Men with established atrial fibrillation or clotting disorders warrant individualized risk-benefit discussions before starting TRT.

The "Celebrity Protocol" vs. Standard of Care

Social media fitness influencers and some men's health clinics market "optimized" or "performance" testosterone protocols that push levels well above the normal physiologic ceiling. These protocols are not supported by the Endocrine Society guidelines and carry meaningfully higher risks of polycythemia, sleep apnea exacerbation, testicular atrophy, and infertility.

The HealthRX clinical team uses a three-tier decision framework for evaluating TRT candidates:

Tier 1 (straightforward candidate): Two morning total T values <300 ng/dL, symptoms present, no contraindications. Initiate testosterone cypionate 100 mg subcutaneous weekly. Recheck labs at 6 weeks and 3 months.

Tier 2 (borderline or complex): Total T 300 to 400 ng/dL, symptoms present, elevated SHBG suspected, or patient has cardiovascular risk factors. Order free testosterone, SHBG, LH, FSH, metabolic panel. Consider 90-day trial with clear symptom endpoints defined before starting.

Tier 3 (refer to endocrinology): Suspected pituitary pathology (low LH/FSH with low T, visual field changes, headache), active fertility desire, prior prostate cancer, hematocrit above 52% at baseline, or prior cardiovascular event within 6 months.

Most men evaluated for TRT in a general telehealth setting fall into Tier 1 or Tier 2.

HGH Speculation: A Separate Clinical Question

Because speculation about Dwayne Johnson frequently pairs TRT with HGH, the two deserve separate clinical treatment.

Human growth hormone secreted by the pituitary peaks in early adulthood and declines roughly 14% per decade thereafter. Adult growth hormone deficiency (AGHD) is a rare, diagnosable condition confirmed by stimulation testing (insulin tolerance test or glucagon stimulation test), not by IGF-1 alone. Molitch ME et al., JCEM 2011.

FDA-approved recombinant HGH (somatropin) for AGHD costs $500 to $2,000 per month depending on brand and dose. Generic biosimilar somatropin products approved since 2021 have begun to reduce that ceiling, but cost remains a significant barrier.

Using HGH outside a diagnosed deficiency for body composition or anti-aging is not FDA-approved, not covered by insurance, and carries risks including fluid retention, carpal tunnel syndrome, glucose intolerance, and, in theory, stimulation of pre-existing malignancies. Prescribing it for those purposes violates federal law under the Anabolic Steroid Control Act provisions that extended to HGH.

The Endocrine Society's position statement is direct: "GH should not be prescribed to healthy adults with age-related decreases in GH secretion solely to restore youthful concentrations." Endocrine Society Position Statement on GH in Adults, referenced via JCEM 2009.

Practical Steps for a Man Considering TRT

Getting started does not require a celebrity trainer or a Beverly Hills concierge physician. The pathway is standardized.

Step 1. Schedule a fasting morning lab draw (7 to 10 a.m.) that includes total testosterone, free testosterone, SHBG, LH, FSH, complete blood count, comprehensive metabolic panel, PSA (if over 40), and lipid panel. Cost at a commercial lab without insurance: $80 to $200.

Step 2. Review results with a physician. If two separate morning total testosterone values are <300 ng/dL and symptoms are present, a discussion of treatment options is appropriate.

Step 3. Choose a formulation based on lifestyle. Weekly self-injection of testosterone cypionate is the lowest-cost, evidence-backed option. Men who travel frequently or dislike needles may prefer gel or pellets at higher cost.

Step 4. Return for monitoring labs at 3 months, then every 6 months once stable. Hematocrit above 54% requires a dose hold or phlebotomy.

Step 5. Set a symptom-based endpoint at initiation. If libido, energy, or body composition have not improved meaningfully after 6 months at therapeutic testosterone levels, additional workup is warranted rather than escalating the dose.

The Endocrine Society recommends against targeting testosterone levels above the upper limit of the normal range (1,000 ng/dL) in any non-research setting. A mid-range value of 500 to 700 ng/dL is a reasonable therapeutic target for most men.